The Spanish Agency of Medicines and Medical Devices has authorised the clinical trial of IDP-121, the first drug blocking and degrading a key oncoprotein in several hematological tumors, including mul...
Read moreUn ensayo clínico internacional controlado aleatorizado de Fase I, en humanos, utilizando DIALIVE -un novedoso dispositivo de diálisis hepática-, demostró su potencial como terapia modificadora de...
Read moreResearchers from VHIO's Experimental Hematology Group have participated in the development of a new technology to manufacture CAR-T cells or genetically modified lymphocytes to attack tumor cells, whi...
Read moreA multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients with multiple myeloma resistant to standard treatmen...
Read moreOryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).
Read moreBlood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial show that ctDNA sequencing can predict cancer drug re...
Read moreLa Fundación ”la Caixa” destinará 4,6 millones de euros a potenciar la investigación en el hospital Clínic Barcelona con el objetivo de desarrollar nuevas terapias personalizadas para diversos...
Read moreThe triple effect of obefazimod would make the drug a potential candidate when designing HIV remission strategies
Read moreLa Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) ha aprobado Elevidys, la primera terapia génica para el tratamiento de la distrofia muscular de Duche...
Read moreA research team from IRB Barcelona and the biotech Nostrum Biodiscovery has developed a new type of inhibitor that blocks only some of the functions of the p38 protein. The alternative pathway that th...
Read moreResearcher has been able to verify that the combination of two drugs, enfortumab vedotin and pembrolizumab, which had previously shown benefits in survival in second-line treatment and in cases of adv...
Read moreMineralys Therapeutics today announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease (CKD), ...
Read more